Today: 9 November 2025
Subscribe
Browse Tag

Pharmaceuticals

Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna, Inc. (NASDAQ: MRNA) posted third‑quarter 2025 revenue of ~$1.02 billion and a GAAP loss of $0.51 per share, topping Wall Street estimates as sales of its updated COVID‑19 vaccine outperformed. The company narrowed its full‑year revenue range to $1.6–$2.0 billion, cut operating‑expense guidance, and raised its year‑end cash outlook. Shares popped in pre‑market trading before wobbling intraday. SEC+1 What happened Moderna’s Q3 print outpaced expectations on both the top and bottom lines, led by stronger‑than‑modeled sales of its updated COVID‑19 shot (marketed this season as mNEXSPIKE/Spikevax 2025–26). Management simultaneously tightened the full‑year revenue band and lowered operating‑expense plans, signaling
6 November 2025
 ·  ·  ·  ·  · 
Roche’s $3.5B Bet on 89bio (ETNB) – Stock Soars to New Highs as NASH Breakthrough Looms

Roche’s $3.5B Bet on 89bio (ETNB) – Stock Soars to New Highs as NASH Breakthrough Looms

Recent Developments and News (Nov 2025) 89bio has dominated biotech headlines in late 2025 due to Roche’s takeover move. On October 30, 2025, Roche announced it had successfully completed a tender offer for 89bio at $14.50/share + a $6.00 CVR, and would immediately merge 89bio into its subsidiary roche.com investing.com. By acquiring over 60% of shares in the tender (and securing another ~27% via guaranteed delivery), Roche was able to execute a short-form merger without a shareholder vote investing.com investing.com. All remaining ETNB shares will convert into the same $14.50 + CVR deal, and 89bio’s stock will cease trading on Nasdaq investing.com
5 November 2025
 ·  ·  ·  · 
Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Financial Health and Earnings Trends Teva’s financial turnaround appears to be gaining steam, driven by both top-line growth and disciplined cost management. Quarterly revenue has now grown year-over-year for 11 straight quarters investing.com, marking a sustained rebound after a difficult past decade. In Q3 2025, revenue rose ~3% YoY (1% in constant currency) to $4.48 B investing.com, while adjusted earnings jumped to $0.78 per share (from $0.69 a year ago) reuters.com. Notably, this beat Wall Street estimates by ~$0.10 and marked Teva’s strongest earnings surprise of 2025 reuters.com. The growth engines are Teva’s newer branded drugs: movement-disorder treatment Austedo, migraine injection
5 November 2025
 ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Once Sky-High Valuation Falters Amid Weight-Loss Drug Headwinds Just a year ago, Novo Nordisk – buoyed by the meteoric success of its weight-loss injection Wegovy – briefly eclipsed all other European companies in market value reuters.com. The Danish pharmaceutical giant enjoyed surging sales as Wegovy and its type-2 diabetes sibling Ozempic (both containing the GLP-1 agonist semaglutide) became global sensations, with millions seeking their dramatic weight-loss benefits. However, 2025 has seen a sharp reversal of fortune. A “slew of headwinds has shaken investor confidence” in Novo Nordisk’s once-dominant growth story stockanalysis.com. The company’s share price has plummeted nearly 50% year-to-date
5 November 2025
 ·  ·  ·  ·  · 
Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Technical Analysis – Levels to Watch From a technical perspective, Pfizer’s stock has been basing in the low-to-mid $20s and has yet to break out of its longer-term downtrend. The 52-week range is roughly $20.92 to $30.43 ts2.tech, and the late-September rally stalled out near the upper-$20s – a zone that now acts as an overhead resistance (around $26–$27). Notably, PFE is trading below its 200-day moving average (~$27), indicating lingering bearish momentum trefis.com. On the upside, a decisive push above the $27–$28 level (and the 200-day MA) would be a bullish signal that the stock’s trend is turning. In
1 November 2025
 ·  ·  ·  ·  · 
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics Stock Explodes on Obesity-Drug Breakthrough – Analysts Eye $10+ Targets

Stock Performance and Recent Movement Rani shares have exploded in the last month. On Oct 1, 2025 RANI traded around $0.50. A landmark collaboration announced Oct 17 with Japan’s Chugai (up to $1.085B deal) and a simultaneous $60M financing sent the stock soaring. Intraday Oct 17 it jumped from $0.47 to $2.39 (+248%) ts2.tech. By Oct 31 the stock closed at $2.20, a 51.7% gain on that day alone ts2.tech. This means RANI is up roughly +20% in the past week (from ~$1.82 on Oct 24 to $2.20) and about +330% in October investing.com investing.com.This rally propelled RANI well above
1 November 2025
 ·  ·  ·  ·  · 
AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

Stock Performance & Technical Trends AbbVie’s stock has been a standout performer in 2025. Shares currently hover around $228–$229, up roughly 28–30% since January and near their highest levels on record ts2.tech reportify.cn. This vastly outperforms both the S&P 500 (up ~16% YTD) and the broader pharma industry (up mid-single-digits) timesunion.com reportify.cn – a testament to investors’ optimism in AbbVie’s post-Humira strategy. The stock’s 52-week range spans from a low of about $163.8 to the recent peak around $244.8 on October 1st ts2.tech. Several catalysts have fueled this rally. In mid-September, AbbVie announced a patent settlement securing no U.S. generics
31 October 2025
 ·  ·  ·  ·  · 
Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Sources: CPHI Frankfurt event coverage contractpharma.com gxpnews.net; GxP News gxpnews.net gxpnews.net; The Medicine Maker/Conexiant conexiant.com conexiant.com; GlobeNewswire (Hengdian/Apeloa) globenewswire.com; Evaluate Pharma forecast evaluate.com evaluate.com; Reuters reuters.com; TechStock² / TS2 Tech ts2.tech ts2.tech; TS2 Tech ts2.tech ts2.tech.
28 October 2025
 ·  ·  ·  · 
Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?

Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?

Key Facts: – Neuphoria (Nasdaq: NEUP) shares plunged ~67% in after-hours trading on Oct 20 when its lead drug BNC210 failed a Phase 3 SAD trial investing.com. The AFFIRM-1 trial missed both primary and secondary endpoints, and the company immediately halted its social anxiety program and launched a full strategic review investing.com globenewswire.com. – CEO Spyros Papapetropoulos vowed to “conserve our cash position” while exploring options to “maximize value for shareholders” globenewswire.com. Neuphoria will evaluate BNC210 in PTSD (where earlier data were promising) and otherwise cut spending. – NEUP stock fell from about $15.40 on Oct 20 to roughly $5
24 October 2025
 ·  ·  ·  ·  · 
AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie (ABBV) Stock Up 28% YTD as New Drug Wins and Analyst Upgrades Fuel Optimism

Key Facts (as of Oct. 23, 2025): Stock Price and Recent Performance AbbVie’s stock has been a standout in 2025. Shares currently hover around $228–$229, up roughly 28% since January and near their highest levels on record directorstalkinterviews.com. By comparison, the S&P 500 healthcare index is up only around half that, so AbbVie is outperforming its sector. The stock’s 52-week high was about $244.8 (reached on Oct. 1) ts2.tech, and its low in the past year was ~$163.8. Notably, AbbVie surged to a record high in mid-September after the company announced a patent settlement ensuring no U.S. generics for its
23 October 2025
 ·  ·  ·  ·  · 
Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies

In summary, Gilead’s share price has rallied on a wave of HIV-related breakthroughs, pipeline achievements, and upbeat guidance. With third-quarter results due Oct. 30, investors will be watching for sustained growth. For now, analysts remain generally optimistic: the consensus rating is “Buy” (with average target ~$125) based on Gilead’s diversified portfolio and innovation investing.com ts2.tech. As management shifts into high gear on oncology and global health programs (e.g. a PEPFAR-backed plan to deliver Yeztugo overseas), the long-term outlook is that Gilead’s multiple drivers will more than offset sector risks. Sources: Recent financial filings and earnings commentary gilead.com stockanalysis.com; industry news
18 October 2025
 ·  ·  ·  · 
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

RANI Stock Price Explodes on Deal News Rani Therapeutics’ stock price skyrocketed on Friday, Oct. 17, after the company unveiled a major partnership and funding news. In pre-market trade, RANI jumped about 150% and continued to rally after the market open tipranks.com. The stock, which had closed at just $0.47 the prior day, briefly hit approximately $1.37 per share – nearly a 3× gain in value google.com. By midday, shares were still trading around the $1.30 level, up almost +180% on the day. This stunning one-day move snapped RANI out of penny-stock territory and back above the Nasdaq’s $1 minimum
17 October 2025
 ·  ·  ·  ·  · 
1 2 3
Go toTop